PTGS2 and cancer: Mechanistically, the activated COX-2/PGE2 pathway leads to therapy resistance mainly through affecting the TME by inducing epithelial–mesenchymal transition (EMT), suppressing anticancer immunity, and regulating cancer stem cell (CSC) homeostasis (122).